{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T14:38:57Z","timestamp":1772548737144,"version":"3.50.1"},"reference-count":0,"publisher":"Universa BV","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,30]]},"abstract":"<jats:p>Irritable bowel syndrome with constipation (IBS-C) is a common subtype of functional bowel disorder associated with substantial symptom burden and reduced quality of life. Management typically begins with dietary and lifestyle modification, laxatives, and antispasmodics; however, many patients experience inadequate relief, underscoring the need for more effective therapies.\nLinaclotide, a synthetic guanylin analog, is an established treatment for IBS-C. By activating guanylate cyclase-C (GCC) receptors on intestinal epithelial cells, it promotes intestinal fluid secretion, accelerates transit, and alleviates visceral hypersensitivity. Randomized controlled trials have demonstrated its efficacy and favorable safety profile, with mild-to-moderate diarrhea and abdominal pain being the most common adverse events. Because clinical trial populations may not fully reflect real-world patient diversity, real-world evidence (RWE) provides valuable complementary data. This review summarizes current RWE on linaclotide in IBS-C, integrating findings from multiple studies to present a comprehensive view of its effectiveness and safety in routine clinical practice.<\/jats:p>","DOI":"10.51821\/89.1.14529","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:34:56Z","timestamp":1772534096000},"page":"65","source":"Crossref","is-referenced-by-count":0,"title":["Linaclotide for irritable bowel syndrome with constipation: integrating realworld evidence into the therapeutic puzzle"],"prefix":"10.51821","volume":"91","author":[{"given":"K","family":"Argyriou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Manolakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Tsakiridou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Kapsoritakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Miltiadis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"27062","published-online":{"date-parts":[[2026,3,2]]},"container-title":["Acta Gastro Enterologica Belgica"],"original-title":[],"deposited":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T10:34:56Z","timestamp":1772534096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ageb.be\/ageb-journal\/ageb-volume\/ageb-article\/2282\/Linaclotide%20for%20irritable%20bowel%20syndrome%20with%20constipation:%20integrating%20realworldevidence%20into%20the%20therapeutic%20puzzle\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,3,2]]},"published-print":{"date-parts":[[2026,3,30]]}},"URL":"https:\/\/doi.org\/10.51821\/89.1.14529","relation":{},"ISSN":["1784-3227","1784-3227"],"issn-type":[{"value":"1784-3227","type":"print"},{"value":"1784-3227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}